Dr Reddys launches generic version of Tobi in US market

The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

Hyderabad: Dr Reddy's Laboratories Ltd. (Dr Reddys), along with its subsidiaries together referred to as "Dr Reddy's") recently announced the launch of Tobramycin Inhalation Solution, USP in the United States' market.

The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA). Tobi is indicated for the management of cystic fibrosis

Also Read: Dr Reddys unveils generic version of Vitamin K1 injection in US

The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Dr Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.

Tobi is a trademark of Mylan.

Also Read: Dr Reddys gets two USFDA observations for Vizag plants